ENDPOINTS

AstraZeneca spotlights first-in-human data for B7-H4-targeting ADC in endometrial cancer

AstraZeneca is fine-tuning plans for a Phase 3 study for its B7-H4-targeting ADC after the drug produced encouraging response and survival results in endometrial cancer patients enrolled in an early study. The 2 mg/kg dose ...

Mar 17, 2025 - 15:34
 0
AstraZeneca spotlights first-in-human data for B7-H4-targeting ADC in endometrial cancer
AstraZeneca is fine-tuning plans for a Phase 3 study for its B7-H4-targeting ADC after the drug produced encouraging response and survival results in endometrial cancer patients enrolled in an early study. The 2 mg/kg dose ...
Read More

Tags:

Previous Article

Daily briefing: Should the Stanford Prison Experiment be retracted?

Next Article

Fluency Isn’t Intelligence in Healthcare

Related Posts

Bayer cautions pharma sales dip this year despite major upcoming launches

Bayer cautions pharma sales dip this year despite major...

Mar 5, 2025  0

Kojin Therapeutics shuts down, citing lack of investor interest and complex science

Kojin Therapeutics shuts down, citing lack of investor ...

Feb 14, 2025  0

Drugmakers tell court to keep hospitals out of their 340B rebate suits

Drugmakers tell court to keep hospitals out of their 34...

Feb 20, 2025  0